Actively Recruiting
Long-term Study of Maridebart Cafraglutide for Weight Management in Adults With Obesity or Overweight
Led by Amgen · Updated on 2026-10-05
3200
Participants Needed
92
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating maridebart cafraglutide for people with obesity or overweight to evaluate its long-term effects on weight management, safety, and tolerability. This trial is an extension of a previous study trial 20210181 and aims to provide more information about how the drug works over an extended period. It is a phase 3, randomized, double-blind study sponsored by Amgen. Participants will receive different doses of maridebart cafraglutide or placebo depending on their treatment in the previous trial. Some will continue with low dose every 4 weeks, others will be re-randomized to receive medium or high doses on schedules of every 4, 8, or 12 weeks, or placebo injections every 4 weeks. Participants who had placebo before will undergo a dose-escalation phase before starting the high dose treatment. During the study, participants will be monitored for changes in body weight, waist circumference, quality of life, and any side effects or adverse events over about 48 weeks of treatment. The trial will assess how well weight loss is maintained and record any treatment-emergent adverse events up to 60 weeks. Participants will have regular visits for injections and safety assessments throughout the study period.
CONDITIONS
Brief Title
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Research Team
A
Amgen Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here